Reimbursement Risks Driving Contingency-Based Deals, GSK Exec Says
Executive Summary
Big pharma's appetite for low-cost, low-risk deals won't abate in 2010, as drug makers look to hedge their development bets and smaller companies need financing alternatives in a cash-constrained environment